From Evidence to Practice: Denosumab in Osteoporosis and Joint Health

Osteoporosis and osteopenia are prevalent conditions in India, particularly among postmenopausal women and the elderly,leading to increased fracture risks and morbidity. Denosumab, a monoclonal antibody, demonstrates superior efficacyover other treatments in reducing fracture risk and enhancing bone mineral density (BMD). Clinical trials highlight itseffectiveness in preventing periprosthetic bone loss, improving implant stability, and mitigating femoral head collapse invarious conditions; combination therapies involving denosumab further amplify BMD gains and reduce fracture risk. Thearticle reviews the efficacy and safety of denosumab in managing osteoporosis, joint replacement therapy, and avascularnecrosis based on a review of clinical evidence and studies. Denosumab emerges as a cornerstone therapy for osteoporosismanagement, offering multifaceted benefits in fracture prevention, joint replacement therapy, and avascular necrosis